Your browser doesn't support javascript.
loading
Efficacy of combined medication of risedronate sodium and selective estrogen receptor modulator on the postmenopausal osteoporosis.
Deng, Yanhua; Li, Lin; Li, Ceng; Wang, Fang; Qu, Yang.
Afiliación
  • Deng Y; Department of Nursing, Jingzhou Chinese Medicine Hospital of Hubei Province, Jingzhou, Hubei, China.
  • Li L; Department of Nursing, Jingzhou Chinese Medicine Hospital of Hubei Province, Jingzhou, Hubei, China.
  • Li C; Department of Orthopedics, Jingzhou Chinese Medicine Hospital of Hubei Province, Jingzhou, Hubei, China.
  • Wang F; Department of Physical Examination, Jingzhou Chinese Medicine Hospital of Hubei Province, Jingzhou, Hubei, China.
  • Qu Y; Department of Orthopedics Medical Center, the 2nd Hospital of Jilin University, Changchun, Jilin, China.
Pak J Pharm Sci ; 33(1(Special)): 495-498, 2020 Jan.
Article en En | MEDLINE | ID: mdl-32173648
To evaluate the efficacy of combined medication of risedronate sodium and raloxifene, a selective estrogen receptor modulator (SERM) on the postmenopausal osteoporosis (PMOP). PMOP patients underwent the combined medication of risedronate sodium and raloxifene (SERM, Treatment group), or only medication of risedronate sodium (Control group). After medication, more significant increases were observed in the bone densities of the lumber vertebra (L1-4) and the neck of left femur of patients in the treatment group. Simultaneously, the levels of estrogen and progesterone in serum decreased sharply in the treatment group. After treatment, P1NP and ß-CTX levels in serum decreased significantly in two groups in comparison with the levels prior to treatment, with evident elevations in the levels of BAP and BGP; similarly, ameliorations in the treatment group were much more evident than those in the control group. In addition, significant declines were identified in the VAS scores of two groups after treatment when comparing to the scores prior to the treatment, and the decline in the treatment group was more evident than that in the control group. Combined medication of risedronate sodium and SERM (raloxifene) performs better in treatment of osteoporosis than the single use of risedronate sodium, without the deterioration of adverse effect of medication.
Asunto(s)
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteoporosis Posmenopáusica / Clorhidrato de Raloxifeno / Moduladores Selectivos de los Receptores de Estrógeno / Ácido Risedrónico Tipo de estudio: Prognostic_studies Límite: Aged / Female / Humans / Middle aged Idioma: En Revista: Pak J Pharm Sci Asunto de la revista: FARMACIA / FARMACOLOGIA / QUIMICA Año: 2020 Tipo del documento: Article País de afiliación: China Pais de publicación: Pakistán
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteoporosis Posmenopáusica / Clorhidrato de Raloxifeno / Moduladores Selectivos de los Receptores de Estrógeno / Ácido Risedrónico Tipo de estudio: Prognostic_studies Límite: Aged / Female / Humans / Middle aged Idioma: En Revista: Pak J Pharm Sci Asunto de la revista: FARMACIA / FARMACOLOGIA / QUIMICA Año: 2020 Tipo del documento: Article País de afiliación: China Pais de publicación: Pakistán